Ozempic vs Wegovy vs Mounjaro vs Zepbound: The Honest 2026 Comparison

The naming situation around GLP-1 medications is genuinely confusing—by design, arguably. Four brand names, but only two drugs. Understanding this distinction is the first step to making an informed choice.

The Naming Confusion: Two Drugs, Four Brand Names

Here's the full picture:

Why the split brand names? Regulatory strategy, mostly. Separate FDA approvals for separate indications allow separate pricing negotiations with insurers and separate insurance coverage pathways. It also allows the companies to market to different patient populations.

Practically: if you have Type 2 diabetes, your doctor writes Ozempic or Mounjaro. If your primary goal is weight loss without T2D, they write Wegovy or Zepbound. Same molecules, different paperwork—and that paperwork matters enormously for insurance.

The Mechanism Difference: GLP-1 vs. Dual GIP+GLP-1

This is where tirzepatide (Mounjaro/Zepbound) genuinely differs from semaglutide (Ozempic/Wegovy)—not just in name.

GLP-1 (glucagon-like peptide-1) agonists slow gastric emptying, suppress appetite via the brain, and stimulate insulin secretion in response to food. Semaglutide is a GLP-1 agonist exclusively.

Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) agonism to the mix. GIP receptors are expressed in fat tissue, brain, and bone, and the combination appears to produce synergistic effects on appetite suppression and metabolic function that go beyond what GLP-1 alone achieves.

In plain terms: tirzepatide works on two hunger/metabolism pathways instead of one, and the clinical trial data reflects this.

The Efficacy Data: What Clinical Trials Actually Show

STEP-1: The Semaglutide Benchmark

The STEP-1 trial (N Engl J Med, 2021) enrolled 1,961 adults with obesity but without diabetes. Over 68 weeks at 2.4mg/week semaglutide (Wegovy dose):

• Average weight loss: 14.9% of body weight
• 83% of participants lost at least 5% of body weight
• 50% lost at least 15%
• Roughly 1 in 3 lost more than 20%

These numbers changed clinical practice. Before this trial, no drug had consistently achieved anything close to surgical-level weight loss. For context, Qsymia (the previous gold standard) averaged about 7-8% weight loss.

SURMOUNT-1: The Tirzepatide Benchmark

SURMOUNT-1 (N Engl J Med, 2022) enrolled 2,539 adults with obesity without diabetes. Over 72 weeks at tirzepatide's maximum 15mg/week dose:

• Average weight loss: 20.9%
• 91% lost at least 5%
• 57% lost at least 20%
• High responders (top quartile) averaged 26-27% weight loss

That 20.9% average is approaching what you'd expect from a sleeve gastrectomy (typically 25-30% at 1 year). This was the moment the medical community started taking tirzepatide very seriously as a bariatric-level intervention.

SURMOUNT-5: The Head-to-Head That Settled the Debate

SURMOUNT-1 and STEP-1 couldn't be directly compared—different patient populations, different trial durations, different study designs. SURMOUNT-5 was the purpose-built head-to-head trial everyone was waiting for.

Published in 2024, SURMOUNT-5 randomized 751 adults with obesity (no diabetes) to either tirzepatide (max 15mg) or semaglutide (max 2.4mg—the Wegovy dose):

• Tirzepatide: 20.2% average weight loss
• Semaglutide: 13.7% average weight loss
• Difference: 6.5 percentage points, statistically significant
• Tirzepatide patients were 1.5x more likely to achieve ≥25% weight loss

This is the data that matters. When someone asks "Ozempic or Mounjaro, which is better for weight loss?"—SURMOUNT-5 is the answer. Tirzepatide won, clearly. The debate was real and now it's over.

Side Effect Comparison

Both drugs produce similar GI side effects—nausea, vomiting, diarrhea, constipation—that are most pronounced during dose escalation and tend to improve over time. The profiles are similar enough that you can't make a meaningful choice between them on tolerability alone.

Tirzepatide appears to have slightly lower rates of GI side effects despite achieving greater weight loss—an unexpected finding that researchers attribute to the GIP component potentially moderating GI effects. Both share the black box warning regarding medullary thyroid cancer (based on rodent data), and both are contraindicated in pregnancy and MEN-2 syndrome.

Cost Comparison in 2026

Here's where things get more complicated, because access programs differ significantly:

The Zepbound vial program deserves special attention. Eli Lilly created a cash-pay pathway specifically for patients without insurance coverage: single-dose vials of tirzepatide at $399/month for 5mg or 7.5mg, $549/month for 10mg or 12.5mg, $699/month for 15mg. These require drawing the drug with a syringe rather than using the auto-injector pen, but the drug is identical. For someone paying out of pocket, this is a significant cost advantage over Wegovy (no vial equivalent exists for semaglutide).

Insurance Coverage Differences

Insurance coverage for these drugs varies more than most patients realize:

• Ozempic and Mounjaro (T2D drugs): Covered by most commercial plans with a T2D diagnosis. Part D covers them for Medicare patients with T2D.
• Wegovy (obesity drug): Coverage is expanding but inconsistent. As of 2026, roughly 50-60% of employer plans cover it, but prior authorization requirements are common. The SELECT trial results (showing cardiovascular benefit) have improved coverage for patients with established cardiovascular disease.
• Zepbound (obesity drug): Similar situation to Wegovy. Medicare covers Zepbound specifically for patients with obesity-related sleep apnea—a carve-out established in 2025.

Who Should Consider Which Drug

With the caveat that this is a conversation to have with your prescriber, here's honest guidance based on the evidence:

Strong case for tirzepatide (Mounjaro/Zepbound):

• Your primary goal is maximum weight loss and you have no insurance coverage for either (Zepbound vials at $399/mo vs Wegovy cash at $1,349/mo is a significant advantage)
• You have Type 2 diabetes with significant insulin resistance (tirzepatide's GIP action improves insulin sensitivity particularly well)
• You've tried semaglutide and achieved less than 10% weight loss
• You want the drug with the stronger evidence base for obesity treatment

Reasonable case for semaglutide (Ozempic/Wegovy):

• Your insurance covers Wegovy specifically (coverage criteria may differ between drugs)
• You have established cardiovascular disease—the SELECT trial (2023) showed Wegovy reduced MACE events by 20%, and no equivalent CV outcome trial exists yet for tirzepatide in obesity
• Your provider has more clinical experience with semaglutide and you prefer a more established track record
• Cost and access favor it in your specific situation

The Honest Bottom Line

On pure efficacy, tirzepatide wins—the data from SURMOUNT-5 is clear and the difference (20.2% vs 13.7%) is clinically meaningful, not marginal. That 6.5 percentage point gap translates to roughly an extra 12 pounds of weight loss for a 180-pound person.

But access and cost often override efficacy in the real world. If your insurance covers Wegovy and not Zepbound, or your doctor is more comfortable with semaglutide, or you had a bad experience with tirzepatide side effects—these are legitimate reasons to choose differently than the trial data might suggest.

What this comparison shouldn't do is make you think all four drugs are interchangeable. They're not. Two different molecules with meaningfully different efficacy profiles, accessed through different insurance pathways, at different real-world costs.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Drug prices and insurance coverage change frequently. The clinical trial data cited is accurate as of publication but research continues to evolve. Consult a licensed healthcare provider before starting, switching, or stopping any medication.